TBUFF-- Die Unbekannte und Brutal günstige BioPerle - 500 Beiträge pro Seite

[Biohero]

Hab wieder eine unbekannte Bioperle entdeckt die wirklich sogut wie keiner kennt was am Volumen zuerkennen ist und genau sowas gefällt mir ,einsteigen bevor die Masse die Aktie entdeckt .

Tribute hat bereits 7 Produkte am Markt inklusive Gambia (gegen Migräne) das vor kurzem auf dem Kanadischen Market erhältlich ist und für guten Umsatz sorgen wird . Und dann haben wir noch Bezalip SR ein Potentieller Blockbuster das bald in USA auf den Markt kommt .

Der Jahresumsatz hat schon die $13 Million geknackt tendenz steigend und das bei einer lächerlichen Marktkap von NUR $19 Million .Nur mal als kleines beispiel Antares verdient hat gerade mal einen Jahresumsatz von 20 Million aber dafür eine Marktkap von $570 Million .

Kein Wunder warum die Insider wie wild diese Aktie kaufen schaut euch den link unten dazu an .

TBUFF sollte mindestens schon jetzt zwischen $4-6 pro aktie notieren .Ich werde mich bemühen die Aktie bekannter zu machen noch habe ich damit nicht angefangen .



Ticker: TBUFF

Marktkap: $19.7M
Kurs: $0.39

Shares Out: 51.0M
Fully Diluted Shares: 68.5M

Insider Ownership: 56.7%


Insider Buying
http://finance.yahoo.com/q/it?s=TBUFF+Insider+Transactions


Presentation May 2013
http://content.stockpr.com/tributepharma/media/0a26f60f9fe2b…


Fact Sheet--MUST READ
http://content.stockpr.com/tributepharma/media/cceaf7664429c…

Specialty Pharma with High Growth,Low Risk Business Model
Tribute primarily licenses products that have already
progressed through significant R&D investment and
in many cases,already received regulatory approval
in Canada or other countries. To date,Tributehas
developed or in -licensed 8 products,7 of which
the Company is currently selling.The Company does not invest heavily in R&D, but rather looks tobenefit after the
R&D risk is mitigated.

Growing Revenues
The Company, formerly known as Stellar Pharmaceuticals,
completed its acquisition of privately held Tribute Pharmaceuticals in December of 2011 and changed its name to Tribute in January 2013. Gross revenues havegrown to $13.1
million for the 12 months ended September 30, 2012 when including
revenues of both companies for the last four quarters. In October of 2012 Tribute launched a key new product, CAMBIA®, for the treatment of migraine headaches, which addresses a $150 million market in Canada and is expected to make a meaningful contribution to revenues in Q4 and beyond.The Company is actively looking to build out its product portfolio to generate additional near term revenues.

Established Sales Infrastructure in Canadian Market
Canada is the 10th largest healthcare market in the
world, driven by its national healthcare plan which covers 100% of its population. It’s a geographic market served by very few specialty pharmaceutical companies.With 24 full time sales people,
Tribute sells and distributes to doctors,hospitals and clinics through out Canada. Leveraging its sales and distribution infrastructure,Tribute negotiates for the exclusive license to sell products developed by companies like Pfizer in the Canadian market.

Significant Potential of Bezalip SR® in U.S.Market
Tribute has licensed the exclusive rights to Bezalip SR,
a drug that lowers cholesterol and triglycerides, in the U.S. and Canada.Tribute now sells Bezalip SR in Canada and is developing
its strategy to obtain FDA approval in the U.S., addressing the $3 billion U.S.fibrate market, a subset of the $20 billion U.S. and Canadian dyslipidemia market.Tribute recognizes Bezalip SR in the U.S as a significant asset and seeks to maximize this opportunity.Bezalip SR is approved in more than 40 countries worldwide.

Accomplished Management Team
Tribute’s management team and board members have
successfully built pharmaceutical companies that have been subsequently sold for valuations over $3 billion. Their industry relationships, expertise in licensing
and building sales forces are key value drivers for the Company.

[Datteljongleur]

Antwort auf Beitrag Nr.: 45.048.185 von Biohero am 15.07.13 17:34:53

Was du so alles unter "günstig" verstehst!!

http://yahoo.brand.edgar-online.com/displayfilinginfo.aspx?F…

TBUFF sollte mindestens schon jetzt zwischen $4-6 pro aktie notieren .

Genau, denn bei dem Zahlenwerk wäre das durchaus berechtigt!

[Biohero]

Antwort auf Beitrag Nr.: 45.048.927 von Datteljongleur am 15.07.13 19:20:13

Hey Dattli du bist schon in Ordnung aber von Biotechs hast du keine Ahnung .


All diese Produkte sind schon am Markt erhältich außer Bezalip in USA und Mycova in Kanada die aber bald folgen .


Produkt Pipeline :

Product Indication Geographic Right Market Size

Bezalip® SR Mixed dyslipidemia US &Canada $20 Billion

NeoVisc® Osteoarthritis of the knee Global $1.4 Billion

Soriatane® Moderate to severe psoriasis Canada $210 Million

Uracyst® Interstitial cystitis Global $151 Million

CAMBIA® Acute migraine headaches Canada $150 Million

Collatamp G® Prevention of post-operative infection Canada $20 Million

Gelfoam® Hemostatic device Canada $30 Million

MycoVa™ Nail fungus Canada $30 Million


Canadian Business Includes 7 Marketed Products Including Recently Launched CAMBIA .Tribute sells products in both the primary care and specialty care markets.CAMBIA was launched in October 2012 to compete in the $150 million Canadian migraine market and is expected to be a key contributor to revenue growth in 2013.CAMBIA is a novel, patent-protected, fast-acting, new treatment option for people suffering from acute migraine attacks.Tribute has also entered into a promotional agreement with Pfizer Canada for the exclusive Canadian promotional rights to Gelfoam® in Canada. MycoVa is currently pending regulatory approval in Canada.

[Biohero]

Tribute wird von einem Top Management geführt was auch massiv aktien von TBUFF besitzt und was mich letztlich überzeugt hat hier zu investieren .


Robert Harris
President &Chief Executive Officer
Founder of privately-held Tribute Pharmaceuticals which was acquired by the Company in 2011. Pharmaceutical industry veteran. Held executive positions at Biovail Corporation including VP of Business Development and GM of Biovail’s Canadian commercial group ,where he helped grow revenues to $150 M within four years, leading to Biovail’s acquisition by Valeant (NYSE:VRX) for $3.2 billion.20 years at Wyeth, now division of Pfizer (NYSE:PFE),where as Director of Sale s of Specialty Care group he built out Canadian market segment.Mr. Harris owns 20% of Tribute.


John Gregory Director
Founded and built King Pharmaceuticals (formerly NYSE:KG) which was recently sold to Pfizer (NYSE:PFE) for $3.6 billion. Grew company from small family business to the world‘s 39th largest pharma company that was
included in S&P 500 Index with revenues over $1 billion.Now managing partner of SJ Strategic Investments , a family owned investment management firm. Mr. Gregory owns 12% of Tribute.

[Biohero]

Langsam aber sicher gehts aufwärts ..

[Biohero]

Volumen hat zugenommen und auch der Kurs steigt zwar langsam aber sicher . 52W hoch liegt bei 0.52 wenn diese geknackt ist dürfte es schnell richtung 0.70++ gehen .

[Biohero]

Antwort auf Beitrag Nr.: 45.122.567 von Biohero am 26.07.13 16:53:56

Wie ich diese kleine unbekannten perlen mag

[Biohero]

Neues 52W hoch erreicht ..In ein paar tagen gibts Quartalszahlen das dürfte weiteren Auftrieb geben ..

[techinvestor69]

Tribute Pharma to be acquired by Pozen for $146M (U.S.)

http://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aTRX-22863…